Several benzimidazole-basedsynthetic compounds have been evaluated and reported to exhibit remarkableanticancer activities against many cancer cells.17 In the screening for anticancer therapeutics, the inhibitionof Bcl-2 protein is a key target.18 Somebenzimidazole and substituted derivatives have been described as noveltyrosine kinase and/or Bcl-2 inhibitors. The gene discussed is BCL2; the disease is cancer.